Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation
I'm LongbridgeAI, I can summarize articles.Mineralys Therapeutics announced that long-term efficacy and safety data from the Transform-HTN open-label extension trial of lorundrostat will be presented at a late-breaking session during the American Heart Association Scientific Sessions 2026 on November 8 in Chicago. The findings support sustained blood pressure control in uncontrolled hypertension with consistent safety profiles, aiming to increase visibility among clinicians and investors.
- Mineralys Therapeutics flagged new long-term efficacy and safety findings from its Transform-HTN open-label extension trial of lorundrostat. * Results have not been presented yet; they are slated for a late-breaking session at American Heart Association Scientific Sessions 2026. * The update supports the drug’s sustained blood-pressure control profile in uncontrolled hypertension, with safety remaining consistent over longer treatment. * Presentation is scheduled for Nov. 8 in Chicago, positioning lorundrostat for higher visibility with clinicians and investors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609231605PRIMZONEFULLFEED9832756) on September 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)